You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: May 23, 2025

Drug Sales Trends for ESOMEPRA MAG


✉ Email this page to a colleague

« Back to Dashboard


Payment Methods and Pharmacy Types for ESOMEPRA MAG (2021)

Revenues by Pharmacy Type

Pharmacy Type Revenues
MAIL-ORDER $17,521,384
INSIDE ANOTHER STORE $107,339,949
[disabled in preview] $287,113,414
This preview shows a limited data set
Subscribe for full access, or try a Trial

Units Sold by Pharmacy Type

Pharmacy Type Units
MAIL-ORDER 289,308
INSIDE ANOTHER STORE 617,806
[disabled in preview] 2,631,398
This preview shows a limited data set
Subscribe for full access, or try a Trial

Revenues by Payment Method

Payment Method Revenues
MEDICAID $18,046,517
MEDICARE $206,663,147
[disabled in preview] $191,731,619
This preview shows a limited data set
Subscribe for full access, or try a Trial
Drug Sales Revenue Trends for ESOMEPRA MAG
Drug Units Sold Trends for ESOMEPRA MAG

Esomeprazole Market Analysis and Sales Projections

Overview of Esomeprazole

Esomeprazole, commonly known by its brand name Nexium, is a proton pump inhibitor (PPI) used to treat various gastrointestinal disorders, including gastroesophageal reflux disease (GERD), peptic ulcers, and other acid-related conditions. Here is a comprehensive analysis of the esomeprazole market, including its current state, growth drivers, regional performance, and future projections.

Market Size and Growth Projections

The global esomeprazole market is anticipated to experience significant growth over the forecast period. As of 2023, the market size was valued at approximately USD 1.91 billion[5].

  • Forecast Period: The market is expected to grow from USD 1.904 billion in 2024 to USD 2.872 billion by 2032, exhibiting a Compound Annual Growth Rate (CAGR) of 5.3%[4].
  • CAGR: The CAGR for the esomeprazole market is projected to be around 5.2% to 5.35% during the forecast period from 2024 to 2030 or 2033, depending on the source[1][4][5].

Impact of COVID-19

The COVID-19 pandemic had an adverse impact on the esomeprazole market globally during its initial phase. Patients faced difficulties in accessing pharmacies, and there was a shortage of medicines due to increased demand. However, the market has since recovered, driven by increased product sales, new product launches, strategic developments, and an increased prevalence of GERD[1][3].

Key Drivers of Market Growth

Several factors are driving the growth of the esomeprazole market:

  • Rising Geriatric Population: The aging population is more vulnerable to gastrointestinal disorders such as GERD and peptic ulcers, leading to an increased demand for esomeprazole. By 2040, the older population in the U.S. is projected to reach 80.8 million and 94.7 million by 2060[1][5].
  • Increasing Prevalence of GERD: GERD is one of the most common gastrointestinal disorders, with a prevalence of approximately 20% of adults in North America. This high prevalence drives the demand for esomeprazole[1][4].
  • Lifestyle Factors: Unhealthy eating habits, obesity, and stress levels contribute to greater incidences of acid-related disorders, further boosting the demand for esomeprazole[5].
  • Advancements in Healthcare Infrastructure: Robust and advanced healthcare infrastructure, especially in North America, supports the market growth by providing better diagnostic resources and encouraging proactive healthcare practices[5].

Regional Performance

North America

North America is the largest market for esomeprazole, accounting for a significant share of the global market. This dominance is attributed to:

  • High Prevalence of GERD and Peptic Ulcers: Around 25 million people in the United States are expected to have peptic ulcers at least once in their lifetime[4].
  • Advanced Healthcare Infrastructure: The region has skilled medical professionals and advanced diagnostic resources, which contribute to the high demand for esomeprazole[5].

Asia Pacific

The Asia Pacific region is expected to be the fastest-growing market for esomeprazole. This growth is driven by:

  • Growing Elderly Population: The increasing elderly population in the region is more susceptible to gastrointestinal disorders.
  • Rising Gastroesophageal Reflux Cases: The region is experiencing an increase in GERD cases, which is driving the demand for esomeprazole[4][5].

Product Segments

Capsules Segment

The capsule segment of the esomeprazole market is expected to witness significant growth due to several advantages:

  • Fast-Acting: Capsules break down more quickly than tablets and are fast-acting.
  • Better Tolerability: Capsules are less likely to have an unpleasant taste or odor.
  • Accessibility: Capsules are available in both branded and generic forms, making them easily accessible and affordable to patients[1][3].

Major Players

The esomeprazole market is dominated by several key players, including:

  • Teva Pharmaceutical Industries Ltd.
  • Amneal Pharmaceuticals LLC
  • Viatris Inc.
  • DAIICHI SANKYO COMPANY, LIMITED
  • Sun Pharmaceutical Industries Ltd.[1]

These companies engage in various market strategies such as product innovation, product differentiation, mergers, acquisitions, partnerships, and strategic alliances to maintain their competitive edge.

Distribution Channels

The market is significantly influenced by the distribution channels, particularly hospitals and clinical pharmacies. These settings have seen a rise in doctor consultations driven by growing government initiatives to promote healthcare infrastructure, which in turn fuels the demand for esomeprazole[4].

Key Takeaways

  • The global esomeprazole market is projected to grow at a CAGR of 5.2% to 5.35% from 2024 to 2030 or 2033.
  • North America holds the largest market share, driven by the high prevalence of GERD and peptic ulcers.
  • The Asia Pacific region is expected to be the fastest-growing market.
  • The capsule segment is anticipated to witness significant growth due to its fast-acting nature and better tolerability.
  • The rising geriatric population and lifestyle factors are key drivers of market growth.

FAQs

1. What is the current size of the esomeprazole market? The global esomeprazole market was valued at approximately USD 1.91 billion in 2023[5].

2. Who are the major players in the esomeprazole market? Major players include Teva Pharmaceutical Industries Ltd., Amneal Pharmaceuticals LLC, Viatris Inc., DAIICHI SANKYO COMPANY, LIMITED, and Sun Pharmaceutical Industries Ltd.[1].

3. Which region is expected to be the fastest-growing market for esomeprazole? The Asia Pacific region is projected to be the fastest-growing market for esomeprazole[1][4][5].

4. What are the key drivers of the esomeprazole market growth? Key drivers include the rising geriatric population, increasing prevalence of GERD, lifestyle factors, and advancements in healthcare infrastructure[1][4][5].

5. Why is the capsule segment expected to grow significantly in the esomeprazole market? The capsule segment is expected to grow due to its fast-acting nature, better tolerability, and availability in both branded and generic forms[1][3].

Sources

  1. Mordor Intelligence: Esomeprazole Market - Size, Share & Brands[1].
  2. Market Research Reports: Esomeprazole Magnesium - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030[2].
  3. Mordor Intelligence: Esomeprazole Market Size | Mordor Intelligence[3].
  4. Polaris Market Research: Esomeprazole Market Size, Share, Global Analysis Report 2024-2032[4].
  5. The Brainy Insights: Esomeprazole Market Size, Trend Analysis, Insights[5].
Last updated: 2025-01-02

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.